title: Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
abstract: The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
authors.affiliation: Serviço de Hematologia, Hospital dos Capuchos, Lisboa, Portugal.
authors.forename: A B
authors.initials: AB
authors.lastname: Sousa
authors.forename: J P
authors.initials: JP
authors.lastname: Fernandes
authors.forename: I
authors.initials: I
authors.lastname: Costa
authors.forename: G
authors.initials: G
authors.lastname: Ferreira
authors.forename: O
authors.initials: O
authors.lastname: Nunes
authors.forename: P
authors.initials: P
authors.lastname: Ribeiro
authors.forename: A
authors.initials: A
authors.lastname: Neves
authors.forename: E
authors.initials: E
authors.lastname: Cruz
authors.forename: F
authors.initials: F
authors.lastname: Aveiro
authors.forename: A S
authors.initials: AS
authors.lastname: Rodrigues
authors.forename: M
authors.initials: M
authors.lastname: Bernardo
authors.forename: A
authors.initials: A
authors.lastname: Conduto
authors.forename: A J
authors.initials: AJ
authors.lastname: Gonçalves
authors.forename: A
authors.initials: A
authors.lastname: Monteiro
authors.forename: M
authors.initials: M
authors.lastname: Sousa
authors.forename: V H
authors.initials: VH
authors.lastname: Soares
authors.forename: J
authors.initials: J
authors.lastname: Veiga
authors.forename: J
authors.initials: J
authors.lastname: Gouveia
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction / Q000379:methods*; D015996:Survival Rate
chemical_list: D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008942:Mitoxantrone